News Column

New Cancer Gene Therapy Study Findings Have Been Reported by Investigators at Zhejiang University (Hypoxia Preconditioning of Mesenchymal Stromal...

July 28, 2014



New Cancer Gene Therapy Study Findings Have Been Reported by Investigators at Zhejiang University (Hypoxia Preconditioning of Mesenchymal Stromal Cells Enhances PC3 Cell Lymphatic Metastasis Accompanied by VEGFR-3/CCR7 Activation)

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in Biotechnology. According to news reporting from Hangzhou, People's Republic of China, by NewsRx journalists, research stated, "Mesenchymal stromal cells (MSCs) in bone marrow may enhance tumor metastases through the secretion of chemokines. MSCs have been reported to home toward the hypoxic tumor microenvironment in vivo."

The news correspondents obtained a quote from the research from Zhejiang University, "In this study, we investigated prostate cancer PC3 cell behavior under the influence of hypoxia preconditioned MSCs and explored the related mechanism of prostate cancer lymphatic metastases in mice. Transwell assays revealed that VEGF-C receptor, VEGFR-3, as well as chemokine CCL21 receptor, CC chemokine receptor 7 (CCR7), were responsible for the migration of PC3 cells toward hypoxia preconditioned MSCs. Knock-in Ccr7 in PC3 cells also improved cell migration in vitro. Furthermore, when PC3 cells were labeled using the hrGfp-lentiviral vector, and were combined with hypoxia preconditioned MSCs for xenografting, it resulted in an enhancement of lymph node metastases accompanied by up-regulation of VEGFR-3 and CCR7 in primary tumors. Both PI3K/Akt/I kappa B alpha and JAK2/STAT3 signaling pathways were activated in xenografts in the presence of hypoxia-preconditioned MSCs. Unexpectedly, the p-VEGFR-2/VEGFR-2 ratio was attenuated accompanied by decreased JAK1 expression, indicating a switching-off of potential vascular signal within xenografts in the presence of hypoxia-preconditioned MSCs. Unlike results from other studies, VEGF-C maintained a stable expression in both conditions, which indicated that hypoxia preconditioning of MSCs did not influence VEGF-C secretion."

According to the news reporters, the research concluded: "Our results provide the new insights into the functional molecular events and signalings influencing prostate tumor metastases, suggesting a hopeful diagnosis and treatment in new approaches."

For more information on this research see: Hypoxia Preconditioning of Mesenchymal Stromal Cells Enhances PC3 Cell Lymphatic Metastasis Accompanied by VEGFR-3/CCR7 Activation. Journal of Cellular Biochemistry, 2013;114(12):2834-2841. Journal of Cellular Biochemistry can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Cellular Biochemistry - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4644)

Our news journalists report that additional information may be obtained by contacting X. Huang, Zhejiang University, Inst Pharmacol Toxicol & Biochem Pharmaceut, Hangzhou 310058, Zhejiang, People's Republic of China. Additional authors for this research include K.K. Su, L.M. Zhou, G.F. Shen, Q. Dong, Y.J. Lou and S. Zheng (see also Biotechnology).

Keywords for this news article include: Hangzhou, People's Republic of China, Asia, Biotechnology, Cancer Gene Therapy, Chemokines, Chemotactic Factors, Connective Tissue Cells, Inflammation Mediators, Lymphatic Metastasis, Stromal Cells, Xenograft, Xenotransplantion

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters